Influence of realistic inspiratory flow profiles on fine particle fractions of dry powder aerosol formulations

Pharmaceutical Research

Volumn 24, Issue 2, 2007, Pages 361-369

  Martin, Gary P ^a   Marriott, Christopher ^a   Zeng, Xian Ming ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b MEDWAY SCHOOL OF PHARMACY   (United Kingdom)

Author keywords

Dry powder inhaler; Fine particle fraction; Flow increase rate; Inertial impaction; Laser diffraction; Peak flow rate

Indexed keywords

ALPHA LACTOSE; MALTOSE; SALBUTAMOL; SORBITOL; TERBUTALINE;

ACCELERATION; AEROSOL; AIRFLOW; ANALYSIS OF VARIANCE; ARTICLE; CONTROLLED STUDY; DECELERATION; DRUG FORMULATION; DRY POWDER; FLOW RATE; HUMAN; LASER DIFFRACTION; LINEAR REGRESSION ANALYSIS; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; AEROSOLS; ALBUTEROL; ANTI-ASTHMATIC AGENTS; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COMPUTER SIMULATION; DRUG CARRIERS; HUMANS; LACTOSE; LASERS; MALTOSE; MODELS, ANATOMIC; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; POWDERS; SORBITOL; TERBUTALINE;

EID: 33846083776     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-006-9156-5     Document Type: Article

References (17)

1. M. Dolovich. Characterisation of medical aerosols: physical and clinical requirements for new inhalers. Aerosol. Sci. Tech. 22:392-399 (1995).
2. A. H. de Boer, D. Gjaltema, and P. Hagedoorn. Inhalation characteristics and their effect on in vitro drug delivery from dry powder inhalers. Part 2: effect of peak flow rate (PIFR) and inspiration time on the in vitro drug release from 3 types of commercial dry powder inhalers. Int. J. Pharm. 138:45-56 (1996).
3. D. L. Ross and R. K. Schultz. Effect of inhalation flow rate on the dosing characteristics of dry powder inhaler (DPI) and metered dose inhaler (MDI) products. J. Aerosol Med. 9:215-226 (1996).
4. A. Brindley, B. S. Sumby, and I. J. Smith. The characterisation of inhalation devices by an inhalation simulator: the Electronic Lung. J. Aerosol Med. 7:197-200 (1994).
5. P. K. P. Burnell, L. Petchey, D. Prime, and B. S. Sumby. Patient inhalation profiles and dose emission characteristics from dry powder inhalers. In B. R. Byron, R. N. Dalby, and S. J. Farr (eds.), Respiratory Drug Delivery V, Phoenix, Arizona, 1996.
6. V. S. Chavan and R. N. Dalby. Effect of rise in simulated inspiratory flow rate and carrier particle size on powder emptying from dry powder inhalers. AAPS PharmSCi 2(10):1-7 (2000).
7. V. S. Chavan and R. N. Dalby. Novel system to investigate the effects of inhaled volume and rates of rise in simulated inspiratory air flow on fine particle output from a dry powder inhaler. AAPS PharmSci 4(6):1-6 (2001).
8. S. P. Newman, A. H. Hollingworth, and A. R. Clarke. Effect of different modes of inhalation on drug delivery from a dry powder inhaler. Int. J. Pharm. 102:127-132 (1994).
9. G. Persson, B. Olsson, and S. Soliman. The impact of inspiratory effort on inspiratory flow through Turbuhaleri in asthmatic patients. Eur. Respir. J. 10:681-684 (1997).
10. B. K. P. Burnell, A. Malton, K. Reavill, and M. H. E. Ball. Design, validation and initial testing of the electronic lungi device. J. Aerosol Sci. 29:1011-1025 (1998).
11. A. Brindley, K. J. Reavill, B. S. Sumby, and I. J. Smith. The in-vitro characterization of inhalation devices using the electronic lungi. In B. R. Byron, R. N. Dalby, and S. J. Farr (eds.), Respiratory Drug Delivery IV, Interpharm, Buffalo Grove, Illinois, 1994.
12. A. H. de Boer, G. K. Bolhuis, D. Gjaltema, and P. Hagedoorn. Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers. Part 3: the effect of flow increase rate (FIR) on the in vitro drug release from the Pulmicort 200 Turbuhaler. Int. J. Pharm. 153:67-77 (1997).
13. W. H. Finlay and M. G. Gehmlich. Inertial sizing of aerosol inhaled from two dry powder inhalers with realistic breath patterns versus constant flow rates. Int. J. Pharm. 210:83-95 (2000).
14. X. M. Zeng, H. B. MacRitchie, C. Marriott, and G. P. Martin. Correlation between inertial impaction and laser diffraction sizing data for aerosolized carrier-based dry powder formulations. Pharm. Res. 23(9):2200-2209 (2006).
15. G. P. Martin, H. B. MacRitchie, C. Marriott, and X. M. Zeng. Characterisation of a carrier-free dry powder aerosol formulation using inertial impaction and laser diffraction. Pharm. Res. 23(9):2210-2219 (2006).
16. D. S. MacArthur and S. G. Fleck. The Electronic Lungi™ Bridging the gap between in vitro and in vivo testing. In Proc. drug delivery to the lungs VI, London, 1995.
17. T. Small, S. Doig, G. J. Gibson, B. Johal, P. K. P. Burnell, and R. Jenkins. Use of inhalation profiles from patients with severe obstructive lung disease using the Diskusi inhaler and Turbuhaler™ inhaler to evaluate device performance ex vivo. In Proc. European Respiratory Society Annual Congress, Berlin, 1997.